SCHEMBL2984264

SCHEMBL2984264

N#Cc1cccnc1Nc1ccc2cc[nH]c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
NPC1 O15118 3/20 0.52
ALDH1A1 P00352 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP3A4 P08684 1/20 0.52
POLB P06746 1/20 0.52
BCL6 P41182 1/20 0.51
PRKCQ Q04759 6/20 0.50
SYK P43405 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
CASP3 P42574 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2975972 0.91 GRM4 (0.54) HPGDNPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL30302592 0.81 SYK (0.50) CYP1A2CYP2D6CYP2C9CYP3A4SYK
SCHEMBL22803860 0.81 SYK (0.50) CYP1A2CYP2D6CYP2C9CYP3A4SYK
SCHEMBL22803996 0.77 SYK (0.49) CYP1A2SYKGRM4EGFRRET
SCHEMBL22777940 0.77 EGFR (0.58) CYP1A2SYKGRM4EGFRRET
SCHEMBL22803847 0.77 SYK (0.49) CYP1A2SYKGRM4EGFRRET
SCHEMBL30302544 0.77 SYK (0.49) CYP1A2SYKGRM4EGFRRET
SCHEMBL30302546 0.77 SYK (0.49) CYP1A2SYKGRM4EGFRRET
SCHEMBL2984262 0.74 PRKCQ (0.55) PRKCQSYKESR1PRKCD
SCHEMBL7204879 0.74 PRKCQ (0.47) PRKCQSYKEGFRRETESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781591-B2 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC (US) 2010-08-24 US disclosed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K7 HPGD 2483/4885NPC1 1800/4885ALDH1A1 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.